DISCUSSION
HF, cardiovascular death, LV systolic dysfunction, hypertensive, heart failure, hypertension
ACUTE MYOCARDIAL INFARCTION, HEART FAILURE, HYPERTENSION
We first examined the association of MW parameters and intensive BP treatment. Our findings indicated a significant reduction in GWI and GCW from phase 1 to phase 2 in the intensive treatment group. The standard treatment group exhibited no significant alterations in GWI and GCW. Intensive treatment was also independently correlated with ΔGWI and ΔGCW. Both groups revealed no significant difference in treatment effects in terms of LVEF and GLS. Therefore, GWI and GCW were more sensitive to the changes during intensive BP treatment than GLS and LVEF. Besides, we also discovered GWW increased and GWE decreased in the two treatment groups from phase 1 to phase 2.Few research examined BP‐lowering treatment mechanisms with MW parameters. The majority of studies examining the effects of treatment on MW parameters utilized prospective, self‐control, before‐and‐after methodologies. In contrast, our research employed a randomized, controlled approach in the subcenter STEP trial. Before‐and‐after treatment effect on sacubitril/valsartan was tested in hemodialysis patients with resistant hypertension using MW parameters.Subclinical LV systolic dysfunction is especially important for clinical prognosis in hypertensive patients with normal LVEF. Among patients without heart failure (HF) at baseline, impaired systolic function based on LVEF or strain assessment was independently correlated with incident HF, acute myocardial infarction, or cardiovascular death including elderly population.A meta‐analysis research included 1140 hypertensive patients (mean age 55.4 years, 50% men, follow‐up 6–36 months) containing 8 studies demonstrated that antihypertensive treatment was associated with the improvement in GLS.In a retrospective cross‐sectional study by Tadic et al.Ding et al. found that GWW was higher in the mild hypertension group (SBP: 140–159 mmHg) and moderate‐to‐severe hypertension group (SBP: ≥160 mmHg) than the control group (SBP: 119.3  ± 10.4 mmHg).